Interleukin-6 stimulates coagulation, not fibrinolysis, in humans

• Published in: Thrombosis and haemostasis Vol. 76; no. 5; p. 738
• Main Authors: Stouthard, J M, Levi, M, Hack, C E, Veenhof, C H, Romijn, H A, Sauerwein, H P, van der Poll, T
• Format: Journal Article
• Language: English
• Published: Germany 01.11.1996
• Subjects: Blood Coagulation - drug effects; Carcinoma, Renal Cell - classification; Carcinoma, Renal Cell - therapy; Cross-Over Studies; Female; Fibrinolysis - drug effects; Humans; Interleukin-6 - pharmacology; Kidney Neoplasms - blood; Kidney Neoplasms - therapy; Male; Middle Aged; Recombinant Proteins - pharmacology
• ISSN: 0340-6245
• DOI: 10.1055/s-0038-1650653

The role of IL-6 as a mediator of haemostatic changes during severe inflammation is controversial. To assess the effect of IL-6 on haemostasis we conducted a controlled cross-over study in eight patients with metastatic renal cell cancer. In all subjects coagulation and fibrinolysis were monitored during and after a 4-h infusion of either 150 micrograms recombinant human (rh) IL-6, or during infusion of saline (control study). Mean maximum IL-6 concentrations were 1418.0 +/- 755.8 pg/ml. Compared to the control study, rhIL-6 induced activation of coagulation as reflected by a 190 +/- 55% increase in the plasma levels of thrombin-antithrombin III complexes (p < 0.001) and by a 24 +/- 11% increase in the plasma levels of in the prothrombin activation fragment F1 + 2 (p < 0.001). In contrast, fibrinolysis was not affected. We conclude that in severe inflammation IL-6 may contribute to the activation of coagulation, whereas other factors mediate changes in fibrinolysis.